Type Whole antibody ATC code none Synonyms claudiximab | Target CLDN18.2 Legal status Investigational ChemSpider none | |
IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.
The drug is in phase II clinical trials as of January 2013.
Preliminary results from the phase II 'FAST' trial in June 2016 suggest it is helpful for advanced gastric cancer (and a phase III trial will be planned).
References
IMAB362 Wikipedia(Text) CC BY-SA